12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer

Potters, Louis; Morgenstern, C.; Calugaru, Emel; Fearn, Paul; Jassal, Anup; Presser, J.; Mullen, E.E.

doi:10.1016/j.juro.2008.03.133

Cited by 184 publications

(98 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 1 shows how the same data from a patient may be interpreted using the current possible different definitions of failure. Postradical prostatectomy failure of treatment is usually defined as a PSA rise above 0.2 ng ml À1 , 19 in this case with the patient deemed as failing at 36 m. The ASTRO definition requires month 48 to have been reached before the patients is censured as failing at 33 m. The ASTROKattan, 20 ASTRO-last call 21 and Houston þ 2 definitions give the following times of failure 30, 48 and 54 m respectively. However, one-third of patients treated with brachytherapy will experience a PSA bounce within the first 3 years, typically of a magnitude of o4 ng ml À1 .…”

Section: Long-term Resultsmentioning

confidence: 99%

State-of-the-art: prostate LDR brachytherapy

Voulgaris

Nobes

Laing

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

This article on low dose rate (LDR) prostate brachytherapy reviews long-term results, patient selection and quality of life issues. Mature results from the United States and United Kingdom are reported and issues regarding definitions of biochemical failure are discussed. Latest data comparing brachytherapy with radical prostatectomy or no definitive treatment and also the risk of secondary malignancies after prostate brachytherapy are presented. Urological parameters of patient selection and quality of life issues concerning urinary, sexual and bowel function are reviewed. The position of prostate brachytherapy next to surgery as a first-line treatment modality is demonstrated.

show abstract

Section: Long-term Resultsmentioning

confidence: 99%

State-of-the-art: prostate LDR brachytherapy

Voulgaris

Nobes

Laing

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…12летняя выживаемость без прогрессирования составила почти 80 %. [12]. Эф фективность брахитерапии в монорежиме подтвердила и группа во главе с N. N. Stone -12летняя БРВ 79,2 % [13].…”

Section: Discussionunclassified

The results of I-125 brachytherapy in patients of moderate-risk prostate cancer

Петровский¹,

Амосова²,

Черняев³

et al. 2017

Zlokač. opuholi

View full text Add to dashboard Cite

“…[17][18][19] Results have been mixed, with some studies suggesting some value and others no value to adding ADT to brachytherapy. 20,21 Data addressing the use of ADT with stereotactic RT are even more limited. Hopefully, with the completion of the RTOG 08-15 trial, the relative value of ADT in doseescalated RT for patients with intermediate-risk PCa will be answered.…”

Section: Long-term Aht Versus Rt Alonementioning

confidence: 99%

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Roach

2014

Cancer

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is now a well‐established standard of care in combination with definitive radiotherapy for patients with unfavorable intermediate‐risk to high‐risk locally advanced prostate cancer. It is also well established that combination modality treatment with ADT and radiotherapy is superior to either of these modalities alone for the treatment of patients with high‐risk locally advanced disease. Current treatment guidelines for prostate cancer in the United States are based on the estimated risk of recurrence and death. This review examines the clinical evidence underpinning the use of ADT and radiotherapy among patients with high‐risk localized and locally advanced disease in the United States. This review also considers the rationale for moving from traditional luteinizing hormone‐releasing hormone agonists to more recently developed gonadotrophin‐releasing hormone antagonists. Cancer 2014;120:1620–1629. © 2014 American Cancer Society.

show abstract

12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer

Cited by 184 publications

References 15 publications

State-of-the-art: prostate LDR brachytherapy

State-of-the-art: prostate LDR brachytherapy

The results of I-125 brachytherapy in patients of moderate-risk prostate cancer

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Contact Info

Product

Resources

About